BLUETTI
Do I have to be an Amazon Prime Member to take advantage of BLUETTI Prime Day deals?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220710005073/en/
The short answer: nope. But if you’d like to grab the Prime Day sales only on Amazon , you’ll need to be an Amazon Prime Member.
BLUETTI confirms its annual shopping event - BLUETTI Prime Day date on July 5 - 15. To help you narrow things down, they've collected the best deals on their official website , from solar power stations, solar panels to various accessories worth your money.
The Best Prime Day Deals From BLUETTI
AC200P - The Most Popular 2kWh Solar Generator Now At The Lowest Price Ever - 1.699€ (was 1.999€)
Packed with a 2kW AC pure sine wave inverter, an enormous 2kWh capacity, and utilizing the most durable, safest LiFePO4 battery chemistry, the BLUETTI AC200P is undoubtedly the most cost-effective solar generator .
It can power all your needs from a household fridge to an 8.000 BTU portable air conditioner without breaking a sweat. Recharging by solar at a blistering speed up to 700W. You can juice up AC200P from zero to full in less than 4 hours with free, clean solar power alone!
AC200MAX - All-round Upgraded Power Beast - 2.099€ (was 2.399€)
With two expansion battery ports, the AC200MAX welcomes up to two BLUETTI B230 (2048Wh each) or B300 (3072Wh each) battery modules, allowing you to build on your system up to 8192Wh!
The AC200MAX allows up to 900W solar input and 400W via the AC wall charger, giving you a stunning 1300W total charging input to recharge it in less than 2 hours.
BLUETTI AC300 & B300 - Power Anything Imaginable - 3.899€ (was 4.299€)
Unlike any BLUETTI solar generator products, the AC300 has no built-in battery, bringing it unprecedented mobility and uniqueness. Every AC300 can accept up to 4 B300 (3072Wh each) battery modules, adding up to a groundbreaking 12288Wh capacity – Covering your whole family’s basic needs for DAYS during emergencies or power outages!
Time to plug into full-time solar life! BLUETTI AC300 is now capable of receiving 2400W of unrivaled solar charging input. The advanced MPPT controller lets you juice up a B300 (3072Wh) battery module as soon as 1,5hrs only with sunshine!
Other units highly recommended on BLUETTI UK & EU Prime Day 2022:
EB55 - 537Wh, 700W | Portable Solar Generator
- £549 (was £599);
EB70 - 716Wh, 1000W | Portable Power Station
- £649 (was £739);
B230 - 2048Wh LFP Expansion Battery
- £1399 (was £1499);
EP500Pro - 5100Wh, 3000W | Home Backup Power
- £5399 (was £5999)
AC200MAX & B230 - 4096Wh, 2200W | Portable Solar Generator
- £3199 (was £3499)
EB55 - 537Wh, 700W | Portable Solar Generator
- 599€ (was 649€);
EB70 - 716Wh, 1.000W | Portable Power Station
- 699€ (was 749€);
B230 - 2.048Wh LFP Expansion Battery
- 1.399€ (was 1.599€);
EP500Pro 5.100Wh, 3.000W | Home Backup Power
- 5.399€ (was 5.999€)
AC200MAX & 2/B230 & 3/SP200 - 6.144Wh, 2.200W | Bundles
- 6.394€ (was 8.249€)
About BLUETTI
With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom